Vass CM, Boeri M, Poulos C, Turner AJ. Matching and weighting in stated preferences for health care. Journal of choice modelling. 2022 Sep;44. doi: 10.1016/j.jocm.2022.100367
Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-world effectiveness of lenvatinib in hepatocellular carcinoma patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2021 Nov 20. doi: 10.1016/j.cgh.2021.11.020
Loria LE, Watson V, Kiso T, Phimister E. Investigating users' preferences for low emission buses: experiences from Europe's largest hydrogen bus fleet. Journal of choice modelling. 2019 Sep;32:100169. doi: 10.1016/j.jocm.2019.05.001
McGowan CE, Edwards TP, Luong MU, Hayashi PH. Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. Clin Gastroenterol Hepatol. 2015 Apr;13(4):799-804. doi: 10.1016/j.cgh.2014.07.056
Layton JB, Klemmer PJ, Christiansen CF, Bomback AS, Baron JA, Sandler RS, Kshirsagar AV. Sodium phosphate does not increase risk for acute kidney injury after routine colonoscopy, compared with polyethylene glycol. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1514-21. doi: 10.1016/j.cgh.2014.01.034
Fortuny J, Johnson CC, Bohlke K, Chow WH, Hart G, Kucera G, Mujumdar U, Ownby D, Wells K, Yood MU, Engel LS. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1154-1159. doi: 10.1016/j.cgh.2007.05.022
Camilleri M, Mangel AW, Fehnel SE, Drossman DA, Mayer EA, Talley NJ. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol. 2007 May 1;5(5):534-40.
Buchner DA, Graboys TB, Johnson K, Mordin MM, Goodman L, Partsch DS, Goss TF. Development and validation of the ITG Health-Related Quality-of- Life Short-Form measure for use in patients with coronary artery disease. Integrated Therapeutics Group. Clin Cardiol. 2001 Aug;24(8):556-63.